10:31 AM EDT, 05/08/2025 (MT Newswires) -- Dyne Therapeutics ( DYN ) reported a Q1 net loss Thursday of $1.05 per diluted share, widening from the loss of $0.81 a year earlier.

Analysts polled by FactSet expected a loss of $0.85.

As of March 31, the company had $677.5 million in cash, cash equivalents and marketable securities, which is expected to fund operations at least into H2 2026.

Shares of the company rose 5.3% in recent Thursday trading.

Price: 9.90, Change: +0.50, Percent Change: +5.32